Paramount plans November layoffs in $2 billion cost-cutting move - NYP
Investing.com -- Ventyx Biosciences (NASDAQ:VTYX) stock was unchanged following the announcement of top-line data from its Phase 2a safety and biomarker trial evaluating VTX3232 in patients with early-stage Parkinson’s disease.
The clinical-stage biotech company reported that the study met its primary objective of demonstrating safety and tolerability, with no drug-related treatment-emergent adverse events observed throughout the dosing period. The trial also achieved its pharmacokinetic and pharmacodynamic endpoints, showing high drug exposures in plasma and cerebral spinal fluid as well as evidence of target engagement with suppression of NLRP3-related biomarkers.
The single-center, open-label Phase 2a study evaluated a 40mg oral daily dose of VTX3232 in ten patients with early-stage Parkinson’s disease over a 28-day treatment period. According to the company, the drug demonstrated an excellent pharmacokinetic profile with steady state concentrations exceeding the IC90 for NLRP3 inhibition by at least three-fold for a full 24 hours post-dose.
"We are thrilled that our Phase 2a data show that a once-daily dose of VTX3232 can safely maintain plasma and CSF levels above the IC90 for IL-1b for 24 hours in patients with early Parkinson’s disease," said Mark Forman, MD, PhD, Chief Medical (TASE:BLWV) Officer at Ventyx.
The company also reported improvements in both motor and non-motor symptoms of Parkinson’s disease as measured by MDS-UPDRS, though these results come from a small, open-label study without placebo control.
Ventyx indicated that planning for a double-blind, placebo-controlled, dose-ranging Phase 2 trial in Parkinson’s disease is underway, with potential expansion into additional neurodegenerative disorders such as Alzheimer’s disease.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.